Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA; Duke Clinical Research Institute, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Duke Clinical Research Institute, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
Vaccine. 2017 Dec 4;35(48 Pt B):6664-6671. doi: 10.1016/j.vaccine.2017.10.020. Epub 2017 Oct 19.
Antipyretics reduce fever following childhood vaccinations; after inactivated influenza vaccine (IIV) they might ameliorate fever and thereby decrease febrile seizure risk, but also possibly blunt the immune response. We assessed the effect of antipyretics on immune responses and fever following IIV in children ages 6 through 47 months.
Over the course of three seasons, one hundred forty-two children, receiving either a single or the first of 2 recommended doses of IIV, were randomized to receive either oral acetaminophen suspension (n = 59) or placebo (n = 59) (double-blinded) or ibuprofen (n = 24) (open-label) immediately following IIV and every 4-8 h thereafter for 24 h. Blood samples were obtained at enrollment and 4 weeks following the last recommended IIV dose. Responses to IIV were assessed by hemagglutination inhibition assay (HAI). Seroprotection was defined as an HAI titer ≥1:40 and seroconversion as a titer ≥1:40 if baseline titer <1:10 or four-fold rise if baseline titer ≥1:10. Participants were monitored for fever and other solicited symptoms on the day of and day following IIV.
Significant differences in seroconversion and post-vaccination seroprotection were not observed between children included in the different antipyretic groups and the placebo group for the vaccine antigens included in IIV over the course of the studies. Frequencies of solicited symptoms, including fever, were similar between treatment groups and the placebo group.
Significant blunting of the immune response was not observed when antipyretics were administered to young children receiving IIV. Studies with larger sample sizes are needed to definitively establish the effect of antipyretics on IIV immunogenicity.
退热剂可降低儿童疫苗接种后的体温;在接种灭活流感疫苗(IIV)后,它们可能会缓解发热,从而降低热性惊厥的风险,但也可能会削弱免疫反应。我们评估了退热剂对 6 至 47 月龄儿童接种 IIV 后的免疫反应和发热的影响。
在三个季节期间,142 名儿童(接受单剂或推荐的 2 剂 IIV 中的第 1 剂)随机分为口服对乙酰氨基酚混悬液(n=59)或安慰剂(n=59)(双盲)或布洛芬(n=24)(开放标签)组,在接种 IIV 后立即使用,并在接下来的 24 小时内每 4-8 小时使用一次。在最后一剂推荐的 IIV 剂量后 4 周采集血样。通过血凝抑制试验(HAI)评估 IIV 反应。血清保护定义为 HAI 滴度≥1:40,血清转化率定义为基线滴度<1:10 时滴度≥1:40 或 4 倍升高,基线滴度≥1:10 时滴度升高≥4 倍。在接种 IIV 当天及之后一天监测参与者的发热和其他症状。
在研究期间,与安慰剂组相比,接受 IIV 的不同退热组的疫苗抗原的血清转化率和接种后血清保护率无显著差异。治疗组与安慰剂组的发热等症状发生率相似。
当给接受 IIV 的幼儿使用退热剂时,未观察到免疫反应明显减弱。需要更大样本量的研究来明确退热剂对 IIV 免疫原性的影响。